Lord, Abbett & Co
SAGE

Lord, Abbett & Co’s Sage Therapeutics SAGE Stock Holding History

Lord, Abbett & Co’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-827,577
Closed -$38.9M – 576
2023
Q2 		$38.9M Buy
827,577
+637,244
+335% +$31.7M 0.13% 222
2023
Q1 		$7.99M Buy
+190,333
New +$8.18M 0.03% 429
2019
Q4 		– Sell
-221,994
Closed -$31.1M – 733
2019
Q3 		$31.1M Sell
221,994
-256,617
-54% -$42.9M 0.11% 317
2019
Q2 		$87.6M Sell
478,611
-142,057
-23% -$24.2M 0.28% 95
2019
Q1 		$98.7M Buy
620,668
+492,910
+386% +$71.4M 0.33% 71
2018
Q4 		$12.2M Sell
127,758
-172,807
-57% -$19.8M 0.04% 498
2018
Q3 		$42.5M Sell
300,565
-240,313
-44% -$37.1M 0.12% 289
2018
Q2 		$84.7M Buy
540,878
+73,024
+16% +$11.5M 0.25% 114
2018
Q1 		$75.4M Sell
467,854
-203,681
-30% -$34.6M 0.22% 122
2017
Q4 		$111M Buy
671,535
+395,870
+144% +$38.4M 0.31% 68
2017
Q3 		$17.2M Sell
275,665
-86,023
-24% -$6.76M 0.05% 513
2017
Q2 		$28.8M Sell
361,688
-332,818
-48% -$24.1M 0.09% 354
2017
Q1 		$49.4M Buy
694,506
+121,452
+21% +$7.11M 0.15% 214
2016
Q4 		$29.3M Sell
573,054
-105,994
-16% -$5M 0.09% 322
2016
Q3 		$31.3M Sell
679,048
-43,752
-6% -$1.78M 0.1% 335
2016
Q2 		$21.8M Buy
722,800
+191,396
+36% +$6.38M 0.07% 395
2016
Q1 		$17M Sell
531,404
-563,879
-51% -$19.8M 0.05% 453
2015
Q4 		$63.9M Buy
1,095,283
+834,915
+321% +$41.4M 0.19% 145
2015
Q3 		$11M Sell
260,368
-826,741
-76% -$50.9M 0.03% 563
2015
Q2 		$79.4M Buy
1,087,109
+907,212
+504% +$58.3M 0.21% 125
2015
Q1 		$9.04M Buy
179,897
+71,671
+66% +$3.08M 0.02% 645
2014
Q4 		$3.96M Buy
+108,226
New +$4.03M 0.01% 774

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lord, Abbett & Co's SAGE Position: Q3 2023 in Review

Lord, Abbett & Co sold out of Sage Therapeutics (SAGE) in Q3 2023, closing a stake of 827,577 shares — an estimated $38.9M sold.

Lord, Abbett & Co first reported a position in SAGE in Q4 2014 and held it in 22 quarters. The position peaked at $111M in Q4 2017. 193 funds tracked by Wall St. Rank hold SAGE as of Q3 2023.

  • Lord, Abbett & Co reported no remaining Sage Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Lord, Abbett & Co sold 827,577 Sage Therapeutics shares in Q3 2023, an estimated $38.9M.
  • Lord, Abbett & Co first reported a position in Sage Therapeutics in Q4 2014 and held it in 22 quarters.
  • Lord, Abbett & Co's Sage Therapeutics position peaked at $111M in Q4 2017.
  • 193 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2023.

Based on Lord, Abbett & Co's 13F filing for Q3 2023, filed 13 Nov 2023.